Aimovig Purple Book BLA 761077

BLA number
761077
Proprietary names
Aimovig
Proper names
erenumab-aooe
Applicant
Amgen Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Aimovigerenumab-aooe351(a)70MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2018-05-17
002Aimovigerenumab-aooe351(a)70MG/MLInjectionSubcutaneousPre-Filled SyringeDiscLicensed2018-05-17
003Aimovigerenumab-aooe351(a)140MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2019-03-11
004Aimovigerenumab-aooe351(a)140MG/MLInjectionSubcutaneousPre-Filled SyringeDiscLicensed2019-03-11

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-07-01U002Aimovig351(a)DiscAmgen Inc.
2023-07-01U004Aimovig351(a)DiscAmgen Inc.
2020-10-01U001Aimovig351(a)RxAmgen, Inc.
2020-10-01U002Aimovig351(a)RxAmgen, Inc.
2020-10-01U003Aimovig351(a)RxAmgen, Inc.
2020-10-01U004Aimovig351(a)RxAmgen, Inc.
2020-05-01R001Aimovig351(a)RxAmgen Inc.
2020-05-01R002Aimovig351(a)RxAmgen Inc.
2020-05-01R003Aimovig351(a)RxAmgen Inc.
2020-05-01R004Aimovig351(a)RxAmgen Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-07-01002Aimovig351(a)DiscLicensed2018-05-17
2023-07-01004Aimovig351(a)DiscLicensed2019-03-11
2020-05-01001Aimovig351(a)RxLicensed2018-05-17
2020-05-01002Aimovig351(a)RxLicensed2018-05-17
2020-05-01003Aimovig351(a)RxLicensed2019-03-11
2020-05-01004Aimovig351(a)RxLicensed2019-03-11